Vaccine

ENA Respiratory Expands Leadership Team and Extends U.S. Department of Defense Funding to Enable Phase II Program of INNA-051 in Community-Acquired Viral Respiratory Infections

-- New $3.8 million DOD contract extension will fund non-clinical safety studies to support a three-month seasonal prophylaxis Phase 2b…

2 years ago

Omega Therapeutics Announces Updates to its Board of Directors

Chris Schade to Assume Role of Chairman of the Board, Succeeding Noubar Afeyan, Ph.D.Michelle C. Werner, CEO of Alltrna, Appointed…

2 years ago

Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel…

2 years ago

Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate

Saint-Herblain (France), August 28, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive…

2 years ago

CancerVAX CEO Ryan Davies Discussed Cancer Immunotherapy with UCLA Physician-Scientist

Dr. Steven Jonas commented about his journey to becoming both a practicing cancer doctor and active cancer researcherLEHI, Utah, Aug.…

2 years ago

Cygnus Technologies Receives 2023 R&D 100 Award for MockV® RVLP Kit

LELAND, N.C., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Cygnus Technologies, part of Maravai LifeSciences (Maravai) (NASDAQ: MRVI), the leading product…

2 years ago

cbdMD, Inc. Suspends Monthly Dividend Payment on Its Series A Cumulative Convertible Preferred Stock

Charlotte, North Carolina--(Newsfile Corp. - August 22, 2023) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA) today announced that its…

2 years ago

60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria

60P was awarded additional U.S. patent protection to further solidify its exclusive rights through 2035 for tafenoquine for prevention of…

2 years ago

Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases

BEDMINSTER, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering…

2 years ago

European Commission Approves TALVEY®▼ (talquetamab), Janssen’s Novel Bispecific Therapy for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Talquetamab, the first bispecific antibody targeting GPRC5D, showed an overall response rate of more than 70 percent with durable responses,…

2 years ago